Table 3.

Projected frequencies (%) of clinical progression events for PSA-detected local-regional stage cases who receive no primary treatment by age and grade. Results from three models.

Age group	Gleason grade	Clinical diagnosis			Metastasis by clinical diagnosis			Prostate cancer death
		FHCRC	MISCAN	UMICH	FHCRC	MISCAN	UMICH	FHCRC	MISCAN	UMICH
50–54	2–7	92	71	93	12	23	5	25	29	34
55–59	2–7	85	67	90	11	19	5	23	26	33
60–64	2–7	77	58	86	11	17	5	20	22	31
65–69	2–7	68	49	80	9	14	5	16	17	28
70–74	2–7	56	40	74	8	10	4	12	12	23
75–79	2–7	44	32	66	6	8	4	8	10	18
80–84	2–7	36	24	59	5	6	3	6	6	13
50–54	8–10	96	96	93	35	23	26	77	83	68
55–59	8–10	90	95	90	33	22	25	69	71	63
60–64	8–10	84	92	86	30	19	24	60	66	56
65–69	8–10	76	89	80	27	21	23	49	55	49
70–74	8–10	66	81	74	23	20	21	39	45	41
75–79	8–10	53	72	66	20	19	19	29	33	32
80–84	8–10	46	64	59	16	17	16	21	23	24